Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2002 Sep;57(9):810–816. doi: 10.1136/thorax.57.9.810

A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK

F Drobniewski 1, I Eltringham 1, C Graham 1, J Magee 1, E Smith 1, B Watt 1
PMCID: PMC1746427  PMID: 12200527

Abstract

Background: This study aimed to describe the clinical, microbiological, molecular epidemiology and treatment of multidrug resistant tuberculosis (MDRTB) cases in the UK and to determine factors associated with survival.

Methods: Ninety MDRTB cases were identified from 1 January 1996 to 30 June 1997; 69 were DNA fingerprinted. Date of diagnosis was determined and data were collated on key demographic factors, clinical, radiological and treatment details. Variables associated with survival were included in a Cox proportional hazards model.

Results: Most of the patients (72.4%) were male, born outside the UK (57.1%), were sputum smear positive (82.2%), and had entered the UK more than 5 years previously (61.9%). Thirty eight of 78 cases (48.7%) had prior TB. Sufficient data on 82 patients were available for survival analysis; 20/27 (74.1%) known to be dead at the end of the observation period had died of tuberculosis. Median survival time overall was 1379 days (95% CI 1336 to 2515) or 3.78 (95% CI 3.66 to 6.89) years (858 days (95% CI 530 to 2515) in immunocompromised individuals (n=32) and 1554 (95% CI 1336 to 2066) days in immunocompetent cases (n=48)). Median survival in patients treated with three drugs to which the bacterium was susceptible on in vitro testing (n=62) was 2066 days (95% CI 1336 to 2515) or 5.66 years, whereas in those not so treated (n=13) survival was 599 days (95% CI 190 to 969) or 1.64 years.

Conclusions: Immunocompromised status, failure to culture the bacterium in 30 days or to apply appropriate three drug treatment, and age were significant factors in mortality. An immunocompromised patient was nearly nine times more likely to die, while application of appropriate treatment reduced the risk (risk ratio 0.06). Increasing age was associated with increasing risk of death (risk ratio 2.079; 95% CI 1.269 to 3.402)—that is, for every 10 year increase in age the risk almost doubled. Overall survival was lower than that reported in previous studies.

Full Text

The Full Text of this article is available as a PDF (107.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Breathnach A. S., de Ruiter A., Holdsworth G. M., Bateman N. T., O'Sullivan D. G., Rees P. J., Snashall D., Milburn H. J., Peters B. S., Watson J. An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. J Hosp Infect. 1998 Jun;39(2):111–117. doi: 10.1016/s0195-6701(98)90324-3. [DOI] [PubMed] [Google Scholar]
  2. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 1998 Jul;53(7):536–548. [PMC free article] [PubMed] [Google Scholar]
  3. Coninx R., Mathieu C., Debacker M., Mirzoev F., Ismaelov A., de Haller R., Meddings D. R. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet. 1999 Mar 20;353(9157):969–973. doi: 10.1016/s0140-6736(98)08341-x. [DOI] [PubMed] [Google Scholar]
  4. Djuretic T., Herbert J., Drobniewski F., Yates M., Smith E. G., Magee J. G., Williams R., Flanagan P., Watt B., Rayner A. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax. 2002 Jun;57(6):477–482. doi: 10.1136/thorax.57.6.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Drobniewski F. A. Diagnosing multidrug resistant tuberculosis in Britain. Clinical suspicion should drive rapid diagnosis. BMJ. 1998 Nov 7;317(7168):1263–1264. doi: 10.1136/bmj.317.7168.1263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Drobniewski F. A., Uttley A. H. Mycobacterial speciation. Methods Mol Biol. 1998;101:323–347. doi: 10.1385/0-89603-471-2:323. [DOI] [PubMed] [Google Scholar]
  7. Drobniewski F. A., Watterson S. A., Wilson S. M., Harris G. S. A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis. J Med Microbiol. 2000 Mar;49(3):271–278. doi: 10.1099/0022-1317-49-3-271. [DOI] [PubMed] [Google Scholar]
  8. Drobniewski F. Is death inevitable with multiresistant TB plus HIV infection? Lancet. 1997 Jan 11;349(9045):71–72. doi: 10.1016/S0140-6736(05)60878-1. [DOI] [PubMed] [Google Scholar]
  9. Dye C., Garnett G. P., Sleeman K., Williams B. G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet. 1998 Dec 12;352(9144):1886–1891. doi: 10.1016/s0140-6736(98)03199-7. [DOI] [PubMed] [Google Scholar]
  10. Espinal M. A., Laszlo A., Simonsen L., Boulahbal F., Kim S. J., Reniero A., Hoffner S., Rieder H. L., Binkin N., Dye C. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001 Apr 26;344(17):1294–1303. doi: 10.1056/NEJM200104263441706. [DOI] [PubMed] [Google Scholar]
  11. Fischl M. A., Uttamchandani R. B., Daikos G. L., Poblete R. B., Moreno J. N., Reyes R. R., Boota A. M., Thompson L. M., Cleary T. J., Lai S. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med. 1992 Aug 1;117(3):177–183. doi: 10.7326/0003-4819-117-3-177. [DOI] [PubMed] [Google Scholar]
  12. Flament-Saillour M., Robert J., Jarlier V., Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med. 1999 Aug;160(2):587–593. doi: 10.1164/ajrccm.160.2.9901012. [DOI] [PubMed] [Google Scholar]
  13. Goble M., Iseman M. D., Madsen L. A., Waite D., Ackerson L., Horsburgh C. R., Jr Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993 Feb 25;328(8):527–532. doi: 10.1056/NEJM199302253280802. [DOI] [PubMed] [Google Scholar]
  14. Kumar D., Watson J. M., Charlett A., Nicholas S., Darbyshire J. H. Tuberculosis in England and Wales in 1993: results of a national survey. Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group. Thorax. 1997 Dec;52(12):1060–1067. doi: 10.1136/thx.52.12.1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Park M. M., Davis A. L., Schluger N. W., Cohen H., Rom W. N. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med. 1996 Jan;153(1):317–324. doi: 10.1164/ajrccm.153.1.8542137. [DOI] [PubMed] [Google Scholar]
  16. Park S. K., Kim C. T., Song S. D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis. 1998 Nov;2(11):877–884. [PubMed] [Google Scholar]
  17. Rose A. M., Watson J. M., Graham C., Nunn A. J., Drobniewski F., Ormerod L. P., Darbyshire J. H., Leese J., Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax. 2001 Mar;56(3):173–179. doi: 10.1136/thorax.56.3.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Salaniponi F. L. The Malawi National Tuberculosis Programme. Bull Int Union Tuberc Lung Dis. 1989 Sep;64(3):40–41. [PubMed] [Google Scholar]
  19. Salomon N., Perlman D. C., Friedmann P., Buchstein S., Kreiswirth B. N., Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis. 1995 Nov;21(5):1245–1252. doi: 10.1093/clinids/21.5.1245. [DOI] [PubMed] [Google Scholar]
  20. Telzak E. E., Sepkowitz K., Alpert P., Mannheimer S., Medard F., el-Sadr W., Blum S., Gagliardi A., Salomon N., Turett G. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med. 1995 Oct 5;333(14):907–911. doi: 10.1056/NEJM199510053331404. [DOI] [PubMed] [Google Scholar]
  21. van Soolingen D., de Haas P. E., Hermans P. W., Groenen P. M., van Embden J. D. Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis. J Clin Microbiol. 1993 Aug;31(8):1987–1995. doi: 10.1128/jcm.31.8.1987-1995.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES